Physician profile
Ari Goldstein
NPI 1922211853
$10,656.90
in general payments reported to CMS, 2019-2025
36 companies · $1,688 in 2025
The $1,688 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,446 · 2020: $1,281 · 2021: $1,278 · 2022: $1,123 · 2023: $1,774 · 2024: $2,068 · 2025: $1,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,529.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,429.22 | 2019-2025 | |
| Gilead Sciences, INC. | $1,275.18 | 2019-2025 | Epclusa, Livdelzi |
| Janssen Biotech, INC. | $1,092.16 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $688.38 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $684.68 | 2019-2024 | Trulance, Plenvu, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $554.47 | 2019-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $300.10 | 2019-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $294.74 | 2023-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $289.18 | 2019-2024 | Linzess |
| Merck Sharp & Dohme LLC | $214.40 | 2020-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $192.21 | 2019-2024 | |
| Braintree Laboratories, INC. | $188.79 | 2019-2023 | Sutab, Suflave |
| Celgene Corporation | $163.79 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $136.86 | 2023-2025 | Ibsrela |
| Redhill Biopharma INC. | $134.42 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $117.12 | 2019-2025 | Rebyota |
| Amgen INC. | $108.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.60 | 2023-2024 | Cyltezo |
| Phathom Pharmaceuticals, INC. | $67.59 | 2024-2025 | Voquezna |
| Organon LLC | $62.82 | 2023-2024 | Hadlima, Renflexis |
| Aimmune Therapeutics, INC. | $57.54 | 2024-2025 | Zenpep |
| Genzyme Corporation | $57.31 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $54.00 | 2025 | Iqirvo |
| Capsovision, INC. | $48.76 | 2024-2025 | Capsocam Plus |
| Lilly USA, LLC | $47.45 | 2025 | Omvoh, Zepbound |
| Alfasigma USA, INC. | $43.27 | 2020 | |
| Allergan, INC. | $40.55 | 2019 | |
| Novo Nordisk INC | $39.53 | 2025 | Wegovy |
| Blueprint Medicines Corporation | $37.03 | 2023 | |
| Ucb, INC. | $35.79 | 2019 | |
| Olympus America INC. | $24.86 | 2025 | Single Use Repositionable Clip |
| Madrigal Pharmaceuticals | $20.20 | 2025 | Rezdiffra |
| Conmed Corporation | $18.26 | 2019 | |
| Nestle Healthcare Nutrition INC. | $15.93 | 2022 | |
| Celltrion USA INC. | $14.75 | 2024 | Zymfentra |
| Shield Therapeutics INC | $13.48 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ari Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.